mirogabalin
Small moleculeexperimental
Mirogabalin is a gabapentinoid medication developed by Daiichi Sankyo. Gabapentin and pregabalin are also members of this class. As a gabapentinoid, mirogabalin binds to the α2δ subunit of voltage-gated calcium channel, but with significantly higher potency than pregabalin. It has shown promising results in Phase II clinical trials for the treatment of diabetic peripheral neuropathic pain. — Wikipedia
Clinical trial activity
18 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
11
Phase 3
9
Phase 4
0
Earliest trial started Nov 1, 2011 (NCT01496365)
Timeline
Indications
Mechanism of action
CACNA2D1 modulator
Chemistry & pharmacology
Loading structure…
SMILES
CCC1=C[C@@H]2[C@H](C1)C[C@]2(CN)CC(=O)O- Mol. weight
- 209.29 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMirogabalin ↗
- ChEMBLCHEMBL3545125 ↗
Also known as
- aminomethyl)-3-ethyl-bicyclo(3.2.0)hept-3-ene-6-acetic acid
- ds-5565
- ds-5565
- ds-5565
- mirogabalin
- mirogabalin
- mirogabalin
- mirogabalin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07307170 | N/A | Dec 15, 2025 | Capital Medical University |
| NCT07157852 | N/A | Sep 5, 2025 | Capital Medical University, China Three Gorges University, Yichang, China, Nanchang University, Peking University |
| NCT06846567 | Phase 1 | Dec 1, 2024 | Government of China |
| NCT06711978 | N/A | Dec 1, 2024 | Pusan National University |
| NCT06328062 | N/A | Apr 1, 2024 | Thammasat University |
| NCT05938088 | N/A | Jul 20, 2023 | Yonsei University |
| NCT04094662 | Phase 3 | Sep 30, 2019 | Daiichi Sankyo |
| NCT03901352 | Phase 3 | Mar 12, 2019 | Daiichi Sankyo |
| NCT02607280 | Phase 3 | Dec 1, 2015 | CMIC Co, Ltd. Japan, Daiichi Sankyo |
| NCT02496884 | Phase 3 | Jun 1, 2015 | Daiichi Sankyo, INC Research |
| NCT02318719 | N/A | Jan 1, 2015 | Daiichi Sankyo, IQVIA, SRL Medisearch |
| NCT02318706 | Phase 3 | Jan 1, 2015 | CMIC Co, Ltd. Japan, Daiichi Sankyo, IQVIA |
| NCT02234583 | Phase 3 | Jan 1, 2015 | Daiichi Sankyo |
| NCT02187159 | Phase 3 | Oct 1, 2014 | Daiichi Sankyo, INC Research |
| NCT02187471 | Phase 3 | Oct 1, 2014 | Daiichi Sankyo, INC Research |
| NCT02146430 | Phase 3 | Oct 1, 2014 | Daiichi Sankyo, INC Research |
| NCT01504412 | Phase 2 | Jan 1, 2012 | Daiichi Sankyo |
| NCT01496365 | Phase 2 | Nov 1, 2011 | Daiichi Sankyo |
Showing 18 of 18 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Daiichi Sankyo | For profit | 12 | 12 | 3 | 2011 |
| INC Research | For profit | 4 | 0 | 1 | 2014 |
| Capital Medical University | Academic/Hospital | 2 | 2 | 1 | 2025 |
| CMIC Co, Ltd. Japan | For profit | 2 | 0 | 1 | 2015 |
| IQVIA | For profit | 2 | 0 | 2 | 2015 |
| China Three Gorges University, Yichang, China | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Government of China | Government | 1 | 1 | 1 | 2024 |
| Nanchang University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Pusan National University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| SRL Medisearch | For profit | 1 | 0 | 1 | 2015 |
| Thammasat University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Yonsei University | Academic/Hospital | 1 | 1 | 1 | 2023 |
13 organizations
Page 1 / 1